Skip to content

Clinical Study on Collagen Peptide of Titan Biotech Limited for Skin, Nail and Hair Health in Adults.

A Double Blind, Prospective, Placebo Controlled, Randomised, Three Arm Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Collagen Peptide of Titan Biotech Limited in the Skin, Nail and Hair Health of Adult Subjects

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/06/019857
Enrollment
78
Registered
2019-06-25
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Collagen Peptide (fish): 5g of product to be dissolved in warm water and consumed once a day, for 90 days Intervention2: Collagen Peptide (Bovine): 5g of product to be dissolved in warm

Sponsors

Titan Biotech Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Adults between 18 and 45 years of age (both ages and all sexes inclusive) 2. Subjects with any skin type with a minimum of one concern i. Wrinkles ii. Dry, Dull Skin iii. Brittle Nails iv. Dry, Dull Hair v. Hair Fall, Breakage vi. Split Ends of the hair 3. Subject/LAR who is willing to give informed consent for participation, able to comprehend and understand the responsibilities during treatment period and follow up period. 4. Subjects who are willing not to participate in any other clinical trial during participation in the current trial.

Exclusion criteria

Exclusion criteria: 1. Subjects with known hypersensitivity to investigational product or its constituents. 2. Subjects who have skin condition that prevent proper examination or evaluation of study criteria. 3. Subjects who are on active treatments for skin and/or hair conditions. 4. Subjects who have dyed their hair in the last 60 days. 5. Subjects with immunucompromised state complications. 6. Any significant medical condition (e.g., significant psychiatric or neurological disorders, active alcohol/drug abuse, etc.), any medical condition that is unstable/poorly controlled or other factor (e.g., planned relocation) that the Investigator felt would interfere with study evaluations and study participation. 7. Females who are pregnant or lactating or planning to become pregnant during the study period. 8. Subjects who mentally unable to comprehend the responsibilities and adhere to the stipulations of the protocol. 9. Subjects, who in the opinion of the Investigator or the Medical Experts are not eligible for enrolment in the study.

Design outcomes

Primary

MeasureTime frame
1. Skin Improvement Questionnaire : Total Score of â?¥20 by end of study 2. 60 Second Hair Count Test: Reduction of â?¥20% by end of study 3. Hair Growth Questionnaire : Total Score of â?¥20 by end of study 4. Nail Health Questionnaire: Total Score of â?¥20 by end of study Timepoint: 1. Skin Improvement Questionnaire : Day1,Day 45, Day 90 2. 60 Second Hair Count Test: Day1,Day 45, Day 90 3. Hair Growth Questionnaire : Day1,Day 45, Day 90 4. Nail Health Questionnaire:Day1,Day 45, Day 90

Secondary

MeasureTime frame
Not applicableTimepoint: Not Applicable

Countries

India

Contacts

Public ContactDr VT Sriraam

Aurous HealthCare R & D India Private Limited

md@auroushealthcare.com9840909155

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026